Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD22-bispecific CAR T cells
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19-CD22-bispecific CAR T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by St. Jude Children's Research Hospital for the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The therapy involves genetically engineering a patient's own T cells to express a bispecific CAR that simultaneously targets two B-cell surface antigens: CD19 and CD22. This dual-targeting approach is designed to mitigate the risk of antigen escape, a common cause of relapse in single-target CAR T therapies where leukemia cells downregulate or lose the target antigen. The treatment process includes lymphodepleting chemotherapy followed by a single infusion of the modified T cells. It is currently being evaluated in a Phase 1 clinical trial (1922CAR) for safety and efficacy in patients aged 21 and younger.
- Other names
- CD19-CD22 chimeric antigen receptor T cellsCD-19-CD22 chimeric antigen receptor T cellsCD 19-CD22 chimeric antigen receptor T cellsCD19-CD22-CAR T cellsCD-19-CD22-CAR T cellsCD 19-CD22-CAR T cellsautologous CD19-CD22-CAR T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19-CD22-bispecific CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD22-bispecific CAR T cells.